Arecor Therapeutics PLC (AREC)

Currency in GBP
75.20
-2.30(-2.97%)
Real-time Data·
AREC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
75.0080.00
52 wk Range
35.40100.00
Key Statistics
Bid/Ask
75.00 / 80.00
Prev. Close
77.5
Open
75.55
Day's Range
75-80
52 wk Range
35.4-100
Volume
5.95K
Average Volume (3m)
95.77K
1-Year Change
37.9817%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AREC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
275.50
Upside
+266.36%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Arecor Therapeutics PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Arecor Therapeutics PLC Company Profile

Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo which is used to treat severe hypoglycaemia events in patients with diabetes; and specialty hospital products. In addition, the company is developing AT247, an ultra-rapid acting insulin, which is in Phase 1 for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. It has a research collaboration with TRx Biosciences Limited for the formulation development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist product; and Medtronic plc to develop a novel thermostable insulin for implantable pump delivery. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.

Compare AREC to Peers and Sector

Metrics to compare
AREC
Peers
Sector
Relationship
P/E Ratio
−3.6x−6.4x−0.5x
PEG Ratio
−0.16−0.100.00
Price/Book
10.3x4.2x2.6x
Price / LTM Sales
5.8x10.3x3.3x
Upside (Analyst Target)
262.5%132.1%48.1%
Fair Value Upside
Unlock0.0%7.7%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 275.50
(+266.36% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Sep 25, 2025
EPS / Forecast
-0.07 / --
Revenue / Forecast
2.00M / --
EPS Revisions
Last 90 days

AREC Income Statement

People Also Watch

1.000
XTR
+5.26%
0.344
ORR
+1.18%
6.11
HVO
+0.16%
21.700
GAGO
-1.36%
1.465
KEFI
+5.70%

FAQ

What Is the Arecor Therapeutics (AREC) Stock Price Today?

The Arecor Therapeutics stock price today is 75.20

What Stock Exchange Does Arecor Therapeutics Trade On?

Arecor Therapeutics is listed and trades on the London Stock Exchange.

What Is the Stock Symbol for Arecor Therapeutics?

The stock symbol for Arecor Therapeutics is "AREC."

What Is the Arecor Therapeutics Market Cap?

As of today, Arecor Therapeutics market cap is 29.26M.

What Is Arecor Therapeutics's Earnings Per Share (TTM)?

The Arecor Therapeutics EPS (TTM) is -0.22.

When Is the Next Arecor Therapeutics Earnings Date?

Arecor Therapeutics will release its next earnings report on Apr 28, 2026.

From a Technical Analysis Perspective, Is AREC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Arecor Therapeutics Stock Split?

Arecor Therapeutics has split 0 times.

How Many Employees Does Arecor Therapeutics Have?

Arecor Therapeutics has 44 employees.

What is the current trading status of Arecor Therapeutics (AREC)?

As of Feb 06, 2026, Arecor Therapeutics (AREC) is trading at a price of 75.20, with a previous close of 77.50. The stock has fluctuated within a day range of 75.00 to 80.00, while its 52-week range spans from 35.40 to 100.00.

What Is Arecor Therapeutics (AREC) Price Target According to Analysts?

The average 12-month price target for Arecor Therapeutics is GBP275.50, with a high estimate of GBP300 and a low estimate of GBP251. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +266.36% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.